Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.97 Million EUR | 9.41% |
| 2022 | 11.86 Million EUR | -31.93% |
| 2021 | 17.42 Million EUR | 2344.32% |
| 2020 | 713 Thousand EUR | 29.64% |
| 2019 | 550 Thousand EUR | -67.46% |
| 2018 | 1.69 Million EUR | -58.64% |
| 2017 | 4.08 Million EUR | 12.97% |
| 2016 | 3.61 Million EUR | 16.53% |
| 2015 | 3.1 Million EUR | -20.31% |
| 2014 | 3.89 Million EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 7.63 Million EUR | -27.45% |
| 2024 Q1 | 9.26 Million EUR | -21.41% |
| 2023 Q3 | 14.53 Million EUR | 59.36% |
| 2023 Q4 | 12.97 Million EUR | -10.72% |
| 2023 FY | 12.97 Million EUR | 9.41% |
| 2023 Q1 | 10.5 Million EUR | -11.47% |
| 2023 Q2 | 9.12 Million EUR | -13.13% |
| 2022 FY | 11.86 Million EUR | -31.93% |
| 2022 Q1 | 16 Million EUR | -8.19% |
| 2022 Q3 | 13.23 Million EUR | -9.91% |
| 2022 Q4 | 11.86 Million EUR | -10.33% |
| 2022 Q2 | 14.68 Million EUR | -8.22% |
| 2021 Q1 | 10.66 Million EUR | 1395.79% |
| 2021 FY | 17.42 Million EUR | 2344.32% |
| 2021 Q4 | 17.42 Million EUR | 67.79% |
| 2021 Q3 | 10.38 Million EUR | -2.25% |
| 2021 Q2 | 10.62 Million EUR | -0.37% |
| 2020 Q2 | 326 Thousand EUR | -20.29% |
| 2020 FY | 713 Thousand EUR | 29.64% |
| 2020 Q1 | 409 Thousand EUR | -25.64% |
| 2020 Q4 | 713 Thousand EUR | 32.28% |
| 2020 Q3 | 539 Thousand EUR | 65.34% |
| 2019 Q3 | 492 Thousand EUR | -13.53% |
| 2019 Q2 | 569 Thousand EUR | -54.81% |
| 2019 Q1 | 1.25 Million EUR | -25.5% |
| 2019 FY | 550 Thousand EUR | -67.46% |
| 2019 Q4 | 550 Thousand EUR | 11.79% |
| 2018 Q3 | 2.24 Million EUR | -21.78% |
| 2018 Q2 | 2.86 Million EUR | -17.6% |
| 2018 Q1 | 3.48 Million EUR | -14.78% |
| 2018 FY | 1.69 Million EUR | -58.64% |
| 2018 Q4 | 1.69 Million EUR | -24.69% |
| 2017 Q3 | 4.68 Million EUR | -11.39% |
| 2017 Q4 | 4.08 Million EUR | -12.73% |
| 2017 FY | 4.08 Million EUR | 12.97% |
| 2017 Q2 | 5.28 Million EUR | 60.12% |
| 2017 Q1 | 3.3 Million EUR | -8.76% |
| 2016 FY | 3.61 Million EUR | 16.53% |
| 2016 Q3 | 1.68 Million EUR | -20.82% |
| 2016 Q2 | 2.12 Million EUR | -15.19% |
| 2016 Q1 | 2.5 Million EUR | -19.17% |
| 2016 Q4 | 3.61 Million EUR | 114.66% |
| 2015 FY | 3.1 Million EUR | -20.31% |
| 2015 Q3 | 3.44 Million EUR | -20.66% |
| 2015 Q2 | 4.33 Million EUR | -3.79% |
| 2015 Q1 | 4.5 Million EUR | 15.74% |
| 2015 Q4 | 3.1 Million EUR | -9.79% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q3 | 3.67 Million EUR | 0.0% |
| 2014 Q4 | 3.89 Million EUR | 6.13% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 FY | 3.89 Million EUR | 0.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 46.746% |
| Dynavax Technologies Corporation | 252.41 Million USD | 94.858% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 64.996% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.839% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 60.902% |
| Perrigo Company plc | 3.63 Billion USD | 99.643% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 71.595% |
| Illumina, Inc. | 1.48 Billion USD | 99.128% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.959% |
| Nektar Therapeutics | 112.62 Million USD | 88.476% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -1197.9% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.9% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 92.53% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 44.862% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 97.812% |
| Waters Corporation | 2.3 Billion USD | 99.437% |
| Biogen Inc. | 7.18 Billion USD | 99.819% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 61.274% |
| Adicet Bio, Inc. | 17.7 Million USD | 26.685% |
| Evolus, Inc. | 120.35 Million USD | 89.216% |
| bluebird bio, Inc. | 224.41 Million USD | 94.217% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -322.219% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 97.412% |
| FibroGen, Inc. | 89.69 Million USD | 85.53% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.525% |
| Homology Medicines, Inc. | 43.17 Million USD | 69.939% |
| Geron Corporation | 35.05 Million USD | 62.971% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.446% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -300.756% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 96.654% |
| Myriad Genetics, Inc. | 130.9 Million USD | 90.085% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.52% |
| OPKO Health, Inc. | 222.03 Million USD | 94.154% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -1286.645% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 86.585% |
| Zoetis Inc. | 6.56 Billion USD | 99.802% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -194.843% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.343% |
| Exelixis, Inc. | 189.94 Million USD | 93.167% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 98.209% |
| uniQure N.V. | 130.06 Million USD | 90.021% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 62.039% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 92.711% |
| Verastem, Inc. | 40.08 Million USD | 67.622% |
| Imunon, Inc. | 1.13 Million USD | -1039.215% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.073% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 98.854% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 94.975% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.134% |
| TG Therapeutics, Inc. | 100.11 Million USD | 87.036% |
| Blueprint Medicines Corporation | 610.96 Million USD | 97.876% |
| Insmed Incorporated | 1.19 Billion USD | 98.912% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 77.225% |
| Incyte Corporation | 29.16 Million USD | 55.493% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 97.093% |